Evidence for the antagonistic form of CXC-motif chemokine CXCL10 in serous epithelial ovarian tumours

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 530-541

  Rainczuk, Adam ^a   Rao, Jyothsna R ^a   Gathercole, Jessica L ^a   Fairweather, Nicole J ^a   Chu, Simon ^a   Masadah, Rina ^b   Jobling, Thomas W ^c   Deb Choudhury, Santanu ^d   Dyer, Jolon ^d   Stephens, Andrew N ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b HASANUDDIN UNIVERSITY   (Indonesia)

^c MONASH MEDICAL CENTRE   (Australia)

^d AGRESEARCH LTD   (New Zealand)

Author keywords

CXCL10; dipeptidyl peptidase; leucocyte; mass spectrometry; ovarian cancer

Indexed keywords

CD45 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10;

AMINO TERMINAL SEQUENCE; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MOTIF; SEQUENCE ANALYSIS; T LYMPHOCYTE; TISSUE MICROARRAY;

EID: 84887999281     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28393     Document Type: Article

References (43)

1. Roett MA, Evans P,. Ovarian cancer: an overview. Am Fam Physician 2009; 80: 609-16.
2. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5: e232.
3. Cho KR,. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med 2009; 133: 1775-81.
4. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
5. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-43.
6. Fialova A, Partlova S, Sojka L, et al. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer 2013; 132: 1070-9.
7. Rainczuk A, Rao J, Gathercole J, et al. The emerging role of CXC chemokines in epithelial ovarian cancer. Reproduction 2012; 144: 303-17.
8. Campanella GS, Colvin RA, Luster AD,. CXCL10 can inhibit endothelial cell proliferation independently of CXCR3. PLoS One 2010; 5: e12700.
9. Yates-Binder CC, Rodgers M, Jaynes J, et al. An IP-10 (CXCL10)-derived peptide inhibits angiogenesis. PLoS One 2012; 7: e40812.
10. Yu DM, Yao TW, Chowdhury S, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS J 2010; 277: 1126-44.
11. Casrouge A, Decalf J, Ahloulay M, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 2011; 121: 308-17.
12. Proost P, Schutyser E, Menten P, et al. Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. Blood 2001; 98: 3554-61.
13. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-13.
14. Furuya M, Suyama T, Usui H, et al. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 2007; 38: 1676-87.
15. Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004; 64: 4010-17.
16. Walser TC, Rifat S, Ma X, et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006; 66: 7701-7.
17. Lambeck AJ, Crijns AP, Leffers N, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res 2007; 13: 2385-91.
18. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
19. Stephens AN, Hannan NJ, Rainczuk A, et al. Post-translational modifications and protein-specific isoforms in endometriosis revealed by 2D DIGE. J Proteome Res 2010; 9: 2438-49.
20. Paule SG, Airey LM, Li Y, et al. Proteomic approach identifies alterations in cytoskeletal remodelling proteins during decidualization of human endometrial stromal cells. J Proteome Res 2010; 9: 5739-47.
21. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.
22. Clement LT,. Isoforms of the CD45 common leukocyte antigen family: markers for human T-cell differentiation. J Clin Immunol 1992; 12: 1-10.
23. Sato E, Fujimoto J, Tamaya T,. Expression of interferon-gamma-inducible protein 10 related to angiogenesis in uterine endometrial cancers. Oncology 2007; 73: 246-51.
24. Sato E, Fujimoto J, Toyoki H, et al. Expression of IP-10 related to angiogenesis in uterine cervical cancers. Br J Cancer 2007; 96: 1735-9.
25. Mortier A, Gouwy M, Van Damme J, et al. Effect of posttranslational processing on the in vitro and in vivo activity of chemokines. Exp Cell Res 2011; 317: 642-54.
26. Denney H, Clench MR, Woodroofe MN,. Cleavage of chemokines CCL2 and CXCL10 by matrix metalloproteinases-2 and -9: implications for chemotaxis. Biochem Biophys Res Commun 2009; 382: 341-7.
27. Cox JH, Dean RA, Roberts CR, et al. Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. J Biol Chem 2008; 283: 19389-99.
28. Van den Steen PE, Husson SJ, Proost P, et al. Carboxyterminal cleavage of the chemokines MIG and IP-10 by gelatinase B and neutrophil collagenase. Biochem Biophys Res Commun 2003; 310: 889-96.
29. Hensbergen PJ, Verzijl D, Balog CI, et al. Furin is a chemokine-modifying enzyme: in vitro and in vivo processing of CXCL10 generates a C-terminally truncated chemokine retaining full activity. J Biol Chem 2004; 279: 13402-11.
30. Loos T, Mortier A, Gouwy M, et al. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokines and new dimension of immunoregulation. Blood 2008; 112: 2648-56.
31. Ajami K, Pitman MR, Wilson CH, et al. Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 2008; 582: 819-25.
32. Kajiyama H, Kikkawa F, Khin E, et al. Dipeptidyl peptidase IV overexpression induces up-regulation of E-cadherin and tissue inhibitors of matrix metalloproteinases, resulting in decreased invasive potential in ovarian carcinoma cells. Cancer Res 2003; 63: 2278-83.
33. Kikkawa F, Kajiyama H, Ino K, et al. Increased adhesion potency of ovarian carcinoma cells to mesothelial cells by overexpression of dipeptidyl peptidase IV. Int J Cancer 2003; 105: 779-83.
34. Kajiyama H, Shibata K, Ino K, et al. The expression of dipeptidyl peptidase IV (DPPIV/CD26) is associated with enhanced chemosensitivity to paclitaxel in epithelial ovarian carcinoma cells. Cancer Sci 2010; 101: 347-54.
35. Bank U, Heimburg A, Wohlfarth A, et al. Outside or inside: role of the subcellular localization of DP4-like enzymes for substrate conversion and inhibitor effects. Biol Chem 2011; 392: 169-87.
36. Wilson CH, Abbott CA,. Expression profiling of dipeptidyl peptidase 8 and 9 in breast and ovarian carcinoma cell lines. Int J Oncol 2012; 41: 919-32.
37. Tomsova M, Melichar B, Sedlakova I, et al. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma. Gynecol Oncol 2008; 108: 415-20.
38. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-9.
39. Melani C, Pupa SM, Stoppacciaro A, et al. An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines. Int J Cancer 1995; 62: 572-8.
40. Bakhru A, Buckanovich RJ, Griggs JJ,. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 2011; 121: 106-11.
41. Ross SA, Ekoe JM,. Incretin agents in type 2 diabetes. Can Fam Physician 2010; 56: 639-48.
42. Lai SW, Chen PC, Liao KF, et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study. Am J Gastroenterol 2012; 107: 46-52.
43. Femia AP, Raimondi L, Maglieri G, et al. Long term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats. Int J Cancer 2013. [Epub ahead of print] doi: 10.1002/ijc.28260.